



46159

Bosentan Patient Registry Discontinuation Form

Complete when patient discontinuing bosentan
Please print in **CAPITALS** and fill in circle, do **NOT** tick

Office Use Only

BPR ID

--	--	--

1. Patient Information (Required)

Title	First Name	Initial Last Name	
DOB (dd/mm/yyyy)		Sex: <input type="radio"/> Male <input type="radio"/> Female	Medicare No. #

2. Patient Contact Details (If changed since last prescription)

Address			
Suburb		Postcode	State
() -			
Phone	Mobile Phone		

3. Alternate Contact Details (If changed since last prescription)

First Name	Last Name	
Address		
Suburb	Postcode	State
() -		
Phone	Mobile Phone	

4. Prescriber Information (Required)

First Name	Last Name	
Address		
Suburb	Postcode	State
() -		
Phone	Fax	
Prescribers Signature	Todays date (dd/mm/yyyy)	

5. Additional Registry Information (Required)

WHO Functional Class <input type="radio"/> I <input type="radio"/> II <input type="radio"/> III <input type="radio"/> IV	Is patient on a transplant waiting list? <input type="radio"/> Yes <input type="radio"/> No
Other PAH specific medications prescribed	Has patient received a transplant? <input type="radio"/> Yes <input type="radio"/> No
<input type="radio"/> epoprostenol <input type="radio"/> sildenafil	If Yes, please indicate type and date? <input type="radio"/> Single
<input type="radio"/> iloprost <input type="radio"/> Other 1	<input type="radio"/> BSLTx
<input type="radio"/> treprostinil <input type="radio"/> Other 2	Transplant Date

6. Discontinuation Information (Required)

Please indicate the reason the patient has discontinued bosentan

- Failed criteria Alternative treatment
 Deceased Patient request
 Adverse event Other
 Transplant

Date of discontinuation / /

*Please indicate date of death here if applicable

Please Note:

As bosentan is a TGA registered drug, it is the responsibility of the physician to report any suspected adverse event, thought to possibly be related to bosentan, directly to ADRAC and/or Actelion Pharmaceuticals. Completion of this discontinuation form should not be considered as a mechanism for reporting of adverse events.